Aveo Pharmaceuticals, Inc.

Xoma Technology Ltd.

Xoma Technologies, Ltd.

Lyne Breault

William M Winston, Jr

Jeno Gyuris

May Han

Jie Lin

Bijan Etemad-Gilbertson

Christine Knuehl

S Kirk Wright

Solly Weiler

Kristan Meetze

Ting Chen

Sylvie Vincent

Steve Bottega

Arnold H Horwitz

Steven Tyler

Jin-Kyeung Woo

Christina Fleet

Michael DePrima

Qing Liu

Jinwei Jiang

James Gifford

Zhigang Weng

Fang Wang

Lorena Lerner

Kerry Whalen

Andrea Boudrow

William M Winston

Steve Botega

Michael Deprima

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Anti-ErbB3 antibodies

Anti-ERBB3 antibodies

The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-ron antibodies

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-RON antibodies

Hepatocyte growth factor (HGF) binding proteins

[object Object]

Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3.

Fibroblast growth factor receptor 3 (FGFR3) binding proteins

Growing community of inventors

Roslindale, MA, United States of America

Lyne Breault